Explore Arvinas-Sponsored Clinical Trials
Find trials that may be relevant for you and your patients.
Arvinas Development Program
Explore our development pipeline of PROTAC® protein degraders.
Enrolling Oncology Clinical Trials
Learn more about our enrolling clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
A phase 3, randomized, open-label study of vepdegestrant (ARV-471) vs fulvestrant in patients with ER+/HER2- advanced breast cancer
A Phase 3, randomized, open-label, study of vepgedestrant (ARV-471) plus palbociclib vs letrozole plus palbociclib in patients with ER+/HER2- Advanced Breast Cancer
A phase 2, open-label, randomized, non-comparative study of neo-adjuvant vepdegestrant (ARV-471) or anastrozole in postmenopausal women with ER+/HER2- localized breast cancer
A phase 1b open-label study of vepdegestrant (ARV-471) in combination with everolimus in patients with ER+/HER2- advanced or metastatic breast cancer
A phase 1b/2 umbrella study of vepdegestrant (ARV-471) in combination with other anticancer treatments in patients with ER+ advanced or metastatic breast cancer